MedPath

Jacobio Completes First Patient Dosage of p53 Y220C Activator in Clinical Trial

Jacobio Pharma has successfully administered the first dose of JAB-30355, a p53 Y220C reactivator, to a patient in its Phase I/IIa clinical trial targeting solid tumors with the p53 Y220C mutation. This marks a significant step in the development of treatments for cancers with this common genetic alteration.

Beijing, Shanghai & Boston, Jul 26, 2024 — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the first patient has been dosed in its Phase I/IIa clinical trial of JAB-30355, a p53 Y220C reactivator, in patients with solid tumors.
P53 is the most frequently altered gene in human cancers, with mutations presented in approximately 50% of all invasive tumors. JAB-30355 is an orally bioavailable small molecule designed to treat patients with solid tumors harboring p53 Y220C mutation.
According to the preclinical results presented by Jacobio at AACR 2024, JAB-30355 is a potent and selective p53 Y220C reactivator. JAB-30355 exhibited dose-dependent anti-tumor activity in multiple CDX and PDX models, with overall good tolerability. The synergistic effect was observed when combined with other anti-cancer agents, indicating a broad potential for combinational therapy with JAB-30355.
Currently, there is only one p53 Y220C activator in phase II stage worldwide. The clinical study of JAB-30335 is being conducted in China and U.S.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

JCR Pharmaceuticals Launches Phase III Trial of Long-Acting Growth Hormone JR-142 in Japan

JCR Pharmaceuticals initiates a Phase III clinical trial in Japan for JR-142, a long-acting growth hormone therapy, marking a key advancement in pediatric endocrinology.
The trial will enroll 54 pediatric patients with growth hormone deficiency, comparing JR-142 to JCR's existing product, Growject®, over a 52-week period.

Jacobio Pharmaceuticals Initiates Clinical Trial for Novel Cancer Drug

Jacobio Pharmaceuticals has commenced a clinical trial for a new cancer drug, marking a significant step in their oncology program.
The trial aims to evaluate the safety and efficacy of the drug in a specific patient population, contributing to the advancement of cancer treatment options.

Jubilant Therapeutics Initiates Global Clinical Trials for JBI-802 and JBI-778

Jubilant Therapeutics has dosed the first patients in Phase I/II trials for JBI-802 in heme-oncology, targeting LSD1 and HDAC6.
JBI-802 previously showed anti-tumor activity in NSCLC patients and is now being developed for essential thrombocythemia and MDS/MPN.

Jubilant Therapeutics Initiates Global Clinical Trials for JBI-802 and JBI-778 in Oncology

Jubilant Therapeutics has dosed the first patients in Phase I/II trials for JBI-802, targeting heme-oncology indications, showcasing their commitment to innovative cancer treatments.
JBI-778, an oral brain-penetrant PRMT5 inhibitor, enters Phase I trials focusing on solid tumors including mEGFR TKI-resistant NSCLC, IDH+ high-grade glioma, and adenoid cystic carcinoma.

Jubilant Therapeutics Initiates Clinical Trials for JBI-802 and JBI-778 in Oncology

Jubilant Therapeutics has dosed the first patients in global clinical trials for JBI-802, a first-in-class CoREST inhibitor, targeting heme-oncology malignancies.
The company also initiated a Phase I clinical trial for JBI-778, a potential best-in-class, brain-penetrant PRMT5 inhibitor, in patients with solid tumors.

Rezatapopt Shows Promise in Targeting Previously 'Undruggable' p53 Mutation in Advanced Solid Tumors

Rezatapopt, a first-in-class p53 Y220C reactivator, targets the once 'undruggable' p53 Y220C mutation, prevalent in about 1% of all cancers, offering a tumor-agnostic approach.
Phase 1 data from the PYNNACLE study demonstrated an overall response rate of 34% in efficacy-evaluable patients treated with rezatapopt monotherapy across various advanced solid tumors.

BridgeBio Oncology Therapeutics Announces First Patient Dosed with BBO-8520 in the ONKORAS-101 Trial for KRASG12C NSCLC

BridgeBio Oncology Therapeutics has dosed the first patient in the ONKORAS-101 trial, studying BBO-8520, a novel treatment for KRASG12C non-small cell lung cancer. This marks a significant step in developing targeted therapies for this prevalent malignancy.

Jacobio Pharma's Glecirasib Shows Promise in KRAS G12C-Mutated NSCLC

Jacobio Pharma's glecirasib demonstrated a confirmed objective response rate (cORR) of 47.9% in second-line non-small cell lung cancer (NSCLC) patients.
The Phase II registrational study of glecirasib showed a median progression-free survival (mPFS) of 8.2 months and a median overall survival (mOS) of 13.6 months.

Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30355 in the US

Jacobio Pharma has received IND approval from the FDA for its self-developed drug JAB-30355, a P53 Y220C activator, marking a significant step towards initiating a Phase I/IIa clinical trial for advanced solid tumors in the US. The drug targets the P53 Y220C mutation, prevalent in approximately 50% of all invasive tumors, and has shown promising results in preclinical studies.

Glecirasib Receives Breakthrough Therapy Designation in China for Pancreatic Cancer

Jacobio Pharma's glecirasib, a KRAS G12C inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China's CDE for pancreatic cancer.
The BTD is specifically for patients with KRAS G12C-mutated pancreatic cancer who have progressed after frontline standard care.

Reference News

[1]
Jacobio Completes First Patient Dosage of p53 Y220C ...
jacobiopharma.com · Jul 26, 2024

Jacobio Pharma announced the first patient dosed in Phase I/IIa trial of JAB-30355, a p53 Y220C reactivator for solid tu...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy